Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aslan Pharmaceuticals Ltd ADR (NQ: ASLN )

0.4798 +0.0248 (+5.45%)
Streaming Delayed Price Updated: 1:42 PM EDT, Apr 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aslan Pharmaceuticals Ltd ADR

< Previous 1 2 3 4 5 Next >
ASLAN Pharmaceuticals Announces Positive Interim Results From Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
ASLAN Pharmaceuticals Announces Receipt of Nasdaq Notice
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
ASLN Stock Earnings: ASLAN Pharma Misses EPS for Q4 2023
ASLN stock results show that ASLAN Pharma missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
Aslan Pharmaceuticals to Present at the 2nd Annual H.C. Wainwright Autoimmune and Inflammatory Disease Virtual Conference: Skin Diseases, Conditions and Disorders
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
Week In Review: Under Pressure From US Congress, WuXi AppTec Resigns From BIO
BIO, the global lobbying organization for biotechnology firms, forced WuXi AppTec to leave the group due to pressure from the US Congress. Also, Boehringer Ingelheim acquired an option to license drug... 
Via Talk Markets
ASLAN Pharmaceuticals Announces $5 Million Registered Direct Offering
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
ASLAN Pharmaceuticals Provides TREK-DX Study Update and Highlights Potential of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
ASLAN Pharmaceuticals Announces New Translational Data on Eblasakimab in COPD and Appoints Leading Respiratory Experts as Scientific Advisors
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
ASLAN Pharmaceuticals Receives Favorable Opinion From the European Patent Office on Composition of Matter Patent Application for Farudodstat
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
ASLAN Pharmaceuticals Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
ASLAN Pharmaceuticals Announces Participation in January Investor Conferences
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
ASLAN Pharmaceuticals Provides Year-End Update on Its Eblasakimab and Farudodstat Programs
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
ASLAN Pharmaceuticals to Participate in the 35th Annual Piper Sandler Healthcare Conference
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
ASLAN Pharmaceuticals Presents New Data on Eblasakimab in Atopic Dermatitis and COPD Translational Models at the 7th Dermatology Drug Development Summit
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
ASLAN Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
ASLAN Pharmaceuticals to Co-Host KOL Panel Discussion Today on Changes in the Clinical Trial and Treatment Landscape for Atopic Dermatitis
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
ASLAN Pharmaceuticals to Co-Host KOL Panel Discussion on Changes in the Clinical Trial and Treatment Landscape for Atopic Dermatitis
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
ASLAN Pharmaceuticals Presents New Data From Phase 2b Study of Eblasakimab in Atopic Dermatitis in Late Breaker Presentation at 32nd European Academy of Dermatology and Venereology Congress
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.